Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Inclusion Criteria

• •Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal, staging criteria is to be based on AJCC 7.
• •Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization (WHO) criteria). Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size. A palpable mass is not required as long as the mass is at least 2 cm in one dimension by radiographic exam.
• •At least 18 years of age.
• •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• •Normal bone marrow and organ function as defined below:
• •* Leukocytes ≥ 3,000/mcL
• •* Absolute neutrophil count ≥ 1,500/mcl
• •* Platelets ≥ 100,000/mcl
• •* Total bilirubin ≤ institutional upper limit of normal (IULN)
• •* AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
• •Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
• •Left ventricular ejection fraction (LVEF) ≥ 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)
• •Baseline corrected QT interval (QTcF) \< 480 ms
• •Women of childbearing potential must agree to undergo pregnancy testing within 14 days of study entry and agree to use adequate contraception (barrier method of birth control, abstinence, not hormonal) prior to study entry and for the duration of study participation as well as chemical LHRH Agonist with goserelin. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• •Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).